About TIMA establishment
TIMA establishment was founded in Liechtenstein in 2001 to promote medical research. The TIMA establishment provides research grants in the field of oxidative stress (antioxidant research) and related diseases. The goal is to contribute to health and longevity by supporting advanced research in medical and pharmaceutical sciences.
Oxidative Stress and Disease
Through respiration, living organisms use oxygen from the atmosphere to burn nutrients in their bodies to produce energy, but they also produce ROS (reactive oxygen species) as a byproduct.
In addition to energy production, ROS can be produced by a variety of external factors, including ultraviolet light, radiation, bacteria, viruses, and air pollution, by lifestyle factors such as smoking and heavy alcohol use, and by disease and stress. The body has the ability to eliminate ROS (antioxidant power), but as the body ages, this function declines, and when ROS production becomes excessive (oxidative stress), it causes cellular damage and the body becomes increasingly rusty.
This rusting is called “aging” and is reported to be associated with more than 150 diseases. Major pathologies include cancer, inflammatory colitis, sleep apnea, diabetes, Alzheimer’s disease, chronic fatigue syndrome, hypertension, amyotrophic lateral sclerosis, and cirrhosis of the liver.
Will the use of antioxidants (antioxidant supplements) to suppress oxidative stress lead to disease prevention and treatment? Our ultimate goal is to contribute to a “society of health and longevity” with a large body of evidence.
Major Developed Products
Antioxidant Supplement “Twendee X”
Twendee X is an antioxidant supplement containing eight useful ingredients including coenzyme Q10, vitamins, and amino acids.
It was evaluated by ICDD (France), a company that researches and measures numerous antioxidants, as having the world’s most powerful antioxidant effect in 2014; in 2019, a clinical trial led by the Japanese Society for the Prevention of Dementia confirmed that it was the first in the world to reduce the progression of mild cognitive impairment, with evidence of Antioxidant Supplement. It has also been confirmed to be effective in a number of allergic diseases that are believed to cause an imbalance in the immune system. In particular, 95% of asthma sufferers who participated in a monitoring survey reported a reduction in the number of asthma attacks.
Contents: Coenzyme Q10, vitamin C, L-glutamine, L-cystine, crystalline cellulose, stabilizer (hydroxypropyl cellulose), magnesium stearate, fumaric acid, succinic acid, micro-silicon dioxide, calcium carboxymethyl cellulose, vitamin B2, niacin
Antioxidant Supplement“Twendee Mtcontrol”
Developed to further expand the uses of the antioxidant formula “Twendee X”, this antioxidant supplement contains 15 useful ingredients including folic acid, vitamin C, and amino acids.
Contents: Maltose (manufactured in Japan), Coenzyme Q10 / Vitamin C, L-Glutamine, L-Cystine, Crystal cellulose, Stabilizer (hydroxypropyl cellulose), Fumaric acid, Succinic acid, Magnesium stearate, Micro silicon dioxide, Lactoferrin (contains some milk ingredients) Calcium carboxymethylcellulose, vitamin B₂, nicotinic acid amide, calcium pantothenate, vitamin B₁, vitamin B₆, folic acid, biotin, vitamin B₁₂
Intellectual Property Initiatives
In order to legally protect and effectively utilize the technology originally developed through long-term research, TIMA is developing activities related to intellectual property such as patents, trademarks, designs, and copyrights on a global basis.
All patents and trademarks related to Twendee X and Twendee Mtcontrll are owned by TIMA establishment.
Address：Alte Churer Strasse 45 FL-9496 Balzers Liechtenstein
Chairman of the Board: Markus Count Matuschka de Greiffenclau
Principal Investigator: Haruhiko Inufusa
The TIMA establishment has supported numerous projects with remarkable results, including gene therapy for glioma brain tumors, research to reduce the health hazards of alcohol, diabetes research, suppression of reactive oxygen species, and development of new antimicrobial agents that do not become drug-resistant.
These studies are mainly based on the results of the research team led by Principal Investigator Haruhiko Inufusa.
>Markus Count Matuschka de Greiffenclau
Since 1990, he has invested in and provided management consulting services to several companies, including Skype.
In 2005, he established TIMA establishment for the purpose of donating to medical research and became the chairman of the board.
He is currently involved in the management of several biotechnology-related companies, including Lysando (http://www.lysando.com), a company that has developed antimicrobials that do not cause drug resistance.
Born in Okayama, Japan, he graduated from the Kinki University School of Medicine with a Doctor of Medicine.
He then became a professor at the Department of Clinical Medicine, Kinki University School of Medicine, a visiting professor at the European Institute of Telesurgery, University of Strasbourg, and a visiting professor at the Department of Surgery, University of Barcelona, Spain. Specially Appointed Professor, Department of Antioxidant Research, Gifu University; Chief Researcher, Antioxidant Research Laboratory, Louis Pasteur Medical Research Center, 2020 (concurrent appointment).
For inquiries regarding joint research, public relations, etc., Please contact us using the form below.